Shkreli Subpoenaed For Congressional Price-Gouging Hearing
A House committee has called former Turing Pharmaceuticals CEO Martin Shkreli and Valeant's interim CEO, Howard Schiller, to testify over sharp increases in drug costs at a hearing on Tuesday. Shkreli became notorious after his company Turing hiked the price of Daraprim, the only approved drug for a rare and sometimes deadly parasitic infection, by 5,000 percent.
The New York Times:
Congress Calls Martin Shkreli To Testify On Rapid Rises In Drug Pricing
The Associated Press:
Price-Hiking Pharma Exec Martin Shkreli Gets House Subpoena
Reuters:
U.S. Congressional Committee Subpoenas Ex-Drug CEO Shkreli
The Wall Street Journal:
Valeant Pharmaceutical Interim CEO To Testify Before Congress Next Week